<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2951">
  <stage>Registered</stage>
  <submitdate>11/10/2010</submitdate>
  <approvaldate>11/10/2010</approvaldate>
  <nctid>NCT01222949</nctid>
  <trial_identification>
    <studytitle>A Pharmacokinetic (PK) Trial in Healthy Asian and Caucasian Volunteers Investigating the PK Profile of Eurartesim</studytitle>
    <scientifictitle>A Phase I, Pharmacokinetic Trial, in Healthy Asian and Caucasian Volunteers for Investigating the Pharmacokinetic Profiles of Eurartesim (40 mg Dihydroartemisinin (DHA)/320 mg Piperaquine (PQ) Phosphate.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ST3073/ST3074-DM09-007</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Malaria, Falciparum</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Eurartesim

Experimental: Asian Healthy Volunteers - Asian males with a body weight = 65 kg (12 subjects) Asian females with a body weight = 65 kg (12 subjects)

Experimental: Caucasian Healthy Volunteers - Caucasian males with a body weight = 65 kg (12 subjects) Caucasian females with a body weight = 65 kg (12 subjects) Caucasian males with a body weight &gt; 65 kg (24 subjects)


Treatment: drugs: Eurartesim
Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 3 Tablets a Day for body weight comprised between 36 and 75 kg, 4 tablets for body weight above 75 kg.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>PK: tmax, Cmax, AUC0-12(DHA), AUC0-24(PQ), AUC0-inf, ?z, t1/2 - DHA evaluation: At pre-dose on day Day 0 and Day 2 and then at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, and 12 hours post-dose.
PQ evaluation: At pre-dose Day 0 and then at 1, 2, 3, 4, 5, 6, 8, 12, and 16 hours post-dose; then at pre-dose Day 1 and Day 2 and finally at 1, 2, 3, 4, 5, 6, 8, 12, and 16 hours post-dose on day 2; on Day 3, 4, 5, 7, 14, 21, 28, 42, 56 and 90.</outcome>
      <timepoint>During the first and last day of drug administration (day 0 and 2) and followed up till Day 90</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Treatment Emergent Adverse Events (TEAEs) - Number of TEAEs and number of Subjects experiencing Adverse Events during all the study period</outcome>
      <timepoint>From Day 0 till Day 90</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hematology and blood chemistry changes respect to baseline values - Abnormalities in hematology (Haemoglobin, Hematocrit,RBC count, White cell count and differential count, Platelets) and clinical chemistry (Protein, Sodium, Potassium, Chloride ,Total Bilirubin, Conjugated Bilirubin, Alanine Aminotransferase, Aspartate Aminotransferase, Total Cholesterol, Glucose, Bicarbonate, Urea, Urate, Lactate Dehydrogenase, Albumin, Globulins, Triglycerides, Creatinine, Alkaline Phosphatase, Gamma glutamyltransferase, Total Calcium, Phosphate, C-reactive protein) will be recorded the day of the last study drug intake and after 30 days from the start of the drug treatment</outcome>
      <timepoint>Day 0, Day 3, Day 28, Day 90</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>QTc interval prolongation - ECG recordings will be obtained at baseline, after the last drug intake and 30 days follow-up to investigate changes in ECG parameters, and specifically QTc interval changes respect to baseline</outcome>
      <timepoint>Day 0, day 3, day 28, day 90</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Caucasian or Asian healthy subjects, Male or female, aged between 18 and 50 years
             (inclusive)

          -  Body Mass Index (BMI) between 19.0 kg/m2 and 27.0 kg/m2 inclusive, with a minimum body
             weight of 36 kg.

          -  Agreed to use two approved methods of contraception

          -  Had given written informed consent to participate in this study in accordance with
             local regulations</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Had received or was anticipated to receive a prescription medication within 14 days
             prior to the start of dosing

          -  Pregnant or lactating (females only)

          -  Abnormal laboratory test results deemed clinically significant at screening

          -  Positive urine drug test or alcohol breath test

          -  Acute therapy for a serious infection within 30 days of study entry

          -  History of significant drug allergies or significant allergic reactions

          -  Had participated in a clinical trial or had received an experimental therapy within 30
             days or 10 half-lives of the drug

          -  Receipt of blood or blood products, or loss or donation of 450 mL or more of blood
             within 90 days before the first dose administration</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>80</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>CMAX, a division of IDT Australia Limited - Adelaide</hospital>
    <hospital>Nucleus Network Limited - Melbourne</hospital>
    <postcode>SA 5000 - Adelaide</postcode>
    <postcode>VIC 3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>sigma-tau i.f.r. S.p.A.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>CPR Pharma Services Pty Ltd, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The Study was designed to evaluate the pharmacokinetics of DHA and PQ in healthy volunteers
      and to assess the effect of ethnicity (Asian vs Caucasian), gender and body weight on the
      relative bioavailability of DHA and PQ.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01222949</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>